Effectiveness of desloratadine 5 mg once daily in patients with symptoms of seasonal allergic rhinitis: Results of a Canadian multicenter, open-label trial

Clinical Therapeutics

Volumn 29, Issue 3, 2007, Pages 419-426

  Keith, Paul K ^a   Luciuk, George ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b BC CHILDREN S HOSPITAL   (Canada)

Author keywords

desloratadine; nasal congestion; seasonal allergic rhinitis

Indexed keywords

ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; DESLORATADINE;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ARTICLE; CANADA; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG USE; FATIGUE; FEMALE; HAY FEVER; HEADACHE; HUMAN; IMMUNOTHERAPY; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NOSE CONGESTION; PRIMARY MEDICAL CARE; QUESTIONNAIRE; RATING SCALE; SCHOOL CHILD; SEASONAL VARIATION; SOMNOLENCE; SYMPTOMATOLOGY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTI-ALLERGIC AGENTS; CANADA; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; QUESTIONNAIRES; RHINITIS, ALLERGIC, SEASONAL; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 34250185348     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(07)80080-4     Document Type: Article

References (20)

1. Bousquet J., van Cauwenberge P., Khaltaev N., and Aria Workshop Group and the World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 108 Suppl 5 (2001) 5147-5334
2. Boulet L.P., Turcotte H., Laprise C., et al. Comparative degree and type of sensitization to common indoor and outdoor allergens in subjects with allergic rhinitis and/or asthma. Clin Exp Allergy. 27 (1997) 52-59
3. Salmun L.M., and Lorber R. 24-Hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis (ISRCTN32042139). BMC Fam Pract. 3 (2002) 14
4. 1-receptor antagonist, in patients with seasonal allergic rhinitis: Assessment during the spring and fall allergy seasons. Clin Drug Investig. 21 (2001) 25-32
5. Nayak A.S., and Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 56 (2001) 1077-1080
6. Horak F., Stubner U.P., Zieglmayer R., and Harris A.G. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol. 109 (2002) 956-961
7. Horak F., Stubner P., Zieglmeyer R., and Harris A.G. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy 58 (2003) 481-485
8. 1 receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials. BMJ 317 (1998) 1624-1629
9. Hampel Jr. F., Howland III W., Van Bavel J., and Ratner P. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol. 14 (2004) 56-63
10. Ratner P.H., Lim J.C., Georges G.C., and Ebastine Study Group. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 105 (2000) 1101-1107
11. van Cauwenberge P., and Juniper E.F. Comparison of the efficacy, safety and quality of life provided by fexo fenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 30 (2000) 891-899
12. Casale T.B., Andrade C., and Qu R. Safety and efficacy of once-daily fexofenadine HCI in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc. 20 (1999) 193-198
13. Berger W.E., Schenkel E.J., Mansfield L.E., and Desloratadine Study Group. Safety and efficacy of des loratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol. 89 (2002) 485-491
14. Schenkel E., Corren J., and Murray J.J. Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion. Allergy Asthma Proc. 23 (2002) 325-330
15. Raphael G.D., Angello J.T., Wu M.M., and Druce H.M. Efficacy of diphenhy dramine vs desloratadine and placebo in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 96 (2006) 606-614
16. Day J.H., Briscoe M.P., Rafeiro E., and Ratz J.D. Comparative clinical efficacy, onset and duration of action of lev ocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int J Clin Pract. 58 (2004) 109-118
17. Layton D., Wilton L., Boshier A., et al. Comparison ofthe risk of drowsiness and sedation between levocetirizine and desloratadine: A prescriptionevent monitoring study in England. Drug Saf. 29 (2006) 897-909
18. Agrawal D.K. Anti-inflammatory properties of desloratadine. Clin Exp Allergy 34 (2004) 1342-1348
19. Affrime M., Gupta S., Banfield C., and Cohen A. A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin Pharmacokinet 41 Suppl 1 (2002) S13-S19
20. Available at:. American Academy of Allergy Asthma and Immunology. Accessed. The allergy report (July 25, 2006). http://www.aaaai.org/ar/default.stm